Efficacy News and Research

RSS

Positive results from BIOTRONIK Pantera Lux Paclitaxel Releasing Balloon study presented at TCT 2011

Six-month results from the DELUX registry and 12-month results from the PEPPER study, both demonstrating excellent safety and efficacy results for the Pantera Lux Paclitaxel Releasing Balloon, were presented on Tuesday and Wednesday at the Transcatheter Cardiovascular Therapeutics (TCT 2011) conference by Dr. Ralph Toelg, MD, Segeberger Heart Center Clinic, Bad Segeberg, Germany, and Prof. Christoph Hehrlein, MD, University Medical Center, Freiburg, Germany, respectively.

10 Nov 2011

Maxygen's MAXY-G34 for Acute Radiation Syndrome not considered for BARDA award

Maxygen, Inc. today announced that it has been advised by the Biomedical Advanced Research and Development Authority (BARDA) that Maxygen's proposal for the development of its MAXY-G34 product candidate as a potential medical countermeasure for Acute Radiation Syndrome (ARS) will not be considered for a contract award.

10 Nov 2011

Positive results from Alkermes VIVITROL addiction study

Alkermes plc today presented positive results from a long-term study of VIVITROL (naltrexone for extended-release injectable suspension) at the 24th Annual U.S. Psychiatric and Mental Health Congress in Las Vegas, NV.

10 Nov 2011

Tailored anti-platelet therapy optimizes treatment for patients wtih common genetic variant

Tailored anti-platelet therapy, made possible through a novel point-of-care genetic test, optimizes treatment for patients who carry a common genetic variant, researchers at the University of Ottawa Heart Institute (UOHI) have found.

10 Nov 2011

Clinton expresses U.S. commitment to creating 'AIDS-free generation,' calls on world to help

Secretary of State Hillary Rodham Clinton, speaking at the NIH on Tuesday, "called on the world to create the first 'AIDS-free generation' by using antiviral drugs, condoms, circumcision and other approaches to stem the spread of HIV," the Washington Post reports.

10 Nov 2011

New epigenetic therapy may treat recurrent metastatic NSCLC

Patients with recurrent metastatic non-small cell lung cancer have a morbid prognosis, but a new epigenetic therapy may have potential in this population, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

10 Nov 2011

Large-scale trials show HPV vaccine effective against multiple strains, could reduce need for screening

"Using GlaxoSmithKline's Cervarix vaccine to protect girls against the human papillomavirus (HPV) that causes cervical cancer is so effective that health authorities could reduce the need for later cervical screening," according to two studies published Wednesday in the journal Lancet Oncology, Reuters reports.

9 Nov 2011

BioSante third quarter net loss increases to $12.7 million

BioSante Pharmaceuticals, Inc. today announced financial results for the third quarter ended September 30, 2011 and provided an update on the Company's pipeline.

9 Nov 2011

Enrollment complete in Anacor's first of two tavaborole Phase 3 trials for onychomycosis

Anacor Pharmaceuticals announced today that it has completed enrollment in the first of two Phase 3 trials of tavaborole (formerly known as AN2690), a topical anti-fungal product candidate for the treatment of onychomycosis.

9 Nov 2011

Positive results from NeuroDerm's ND0611 Phase I/II study for advanced Parkinson's disease

NeuroDerm, Ltd. announced today the results of a Phase I/II safety and pharmacokinetic trial of ND0611, administered as an adjunct therapy to Sinemet, Sinemet CR or Stalevo, in patients with advanced Parkinson's disease.

9 Nov 2011

Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced data from a Phase II study of apremilast, its investigational oral immunomodulatory compound, in patients with ankylosing spondylitis (AS) were presented at the American College of Rheumatology Scientific Meeting in Chicago, IL.

9 Nov 2011

BioMimetic Therapeutics reports third quarter total revenues of $0.4M

BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, today reported its financial results as of and for the three and nine months ended September 30, 2011.

9 Nov 2011

Infinity third quarter total revenue increases marginally to $23.3 million

Infinity Pharmaceuticals, Inc. today highlighted its recent clinical and business progress and announced its third quarter 2011 financial results.

9 Nov 2011

Salix third quarter total product revenue increases 81% to $146.2 million

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the third quarter ended September 30, 2011 and other business updates.

9 Nov 2011

Pfizer's Toviaz Study A0221048 for overactive bladder meets primary endpoint

Pfizer Inc. announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 - Effectiveness and Safety of a Flexible Dose Regimen for Patients with Overactive Bladder including Nocturnal Urinary Urgency.

9 Nov 2011

Micromet third quarter total revenues decrease to $4.5 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the third quarter and nine months ended September 30, 2011.

9 Nov 2011

Micell announces preliminary data from MiStent Sirolimus DES clinical study

Micell Technologies, Inc. today announced the release of preliminary data from the first-in-human clinical study of the MiStent Sirolimus Drug Eluting Coronary Stent System (MiStent DES), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed for controlled drug release.

9 Nov 2011

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Bristol-Myers Squibb Company today announced interim results from a Phase IIb clinical trial (COMMAND-1) of 395 treatment-naïve, genotype 1 and 4 hepatitis C infected patients in which two doses of the investigational NS5A replication complex inhibitor daclatasvir (BMS-790052), in combination with peginterferon alfa and ribavirin (alfa/RBV), achieved higher virologic response rates through Week 12 than the alfa/RBV control group, with comparable rates of adverse events.

9 Nov 2011

Positive results from ChemoCentryx CCX354 Phase II study on RA

ChemoCentryx, Inc., today announced that it reported positive Phase II results for CCX354 at the Annual Meeting of the American College of Rheumatology.

9 Nov 2011

Micromet's blinatumomab data to be reported at 53rd ASH annual meeting

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab (MT103) will be reported at the 53rd Annual American Society of Hematology (ASH) Annual Meeting, to be held December 10 - 13 in San Diego, California.

9 Nov 2011

Efficacy News and Research

Positive results from BIOTRONIK Pantera Lux Paclitaxel Releasing Balloon study presented at TCT 2011

Maxygen's MAXY-G34 for Acute Radiation Syndrome not considered for BARDA award

Positive results from Alkermes VIVITROL addiction study

Tailored anti-platelet therapy optimizes treatment for patients wtih common genetic variant

Clinton expresses U.S. commitment to creating 'AIDS-free generation,' calls on world to help

New epigenetic therapy may treat recurrent metastatic NSCLC

Large-scale trials show HPV vaccine effective against multiple strains, could reduce need for screening

BioSante third quarter net loss increases to $12.7 million

Enrollment complete in Anacor's first of two tavaborole Phase 3 trials for onychomycosis

Positive results from NeuroDerm's ND0611 Phase I/II study for advanced Parkinson's disease

Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis

BioMimetic Therapeutics reports third quarter total revenues of $0.4M

Infinity third quarter total revenue increases marginally to $23.3 million

Salix third quarter total product revenue increases 81% to $146.2 million

Pfizer's Toviaz Study A0221048 for overactive bladder meets primary endpoint

Micromet third quarter total revenues decrease to $4.5 million

Micell announces preliminary data from MiStent Sirolimus DES clinical study

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Positive results from ChemoCentryx CCX354 Phase II study on RA

Micromet's blinatumomab data to be reported at 53rd ASH annual meeting

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News